Research ArticleClinical Investigation
68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Sebastian Bauer, Uta Dirksen, Fadi Zarrad, Michael Nader, Michal Chodyla, Aleksandar Milosevic, Lale Umutlu, Martin Schuler, Lars Erik Podleska, Hans-Ulrich Schildhaus, Wolfgang P. Fendler and Rainer Hamacher
Journal of Nuclear Medicine January 2022, 63 (1) 89-95; DOI: https://doi.org/10.2967/jnumed.121.262096
Lukas Kessler
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Justin Ferdinandus
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Nader Hirmas
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Sebastian Bauer
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
Uta Dirksen
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
4Department of Pediatrics III, West German Cancer Center, University Hospital Essen, Essen, Germany;
Fadi Zarrad
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Michael Nader
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Michal Chodyla
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
5Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
Aleksandar Milosevic
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
5Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
Lale Umutlu
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
5Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
Martin Schuler
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
Lars Erik Podleska
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
6Department of Tumor Orthopedics and Sarcoma Surgery, University Hospital Essen, Essen, Germany; and
Hans-Ulrich Schildhaus
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
7Department of Pathology, University Hospital Essen, Essen, Germany
Wolfgang P. Fendler
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
Rainer Hamacher
2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 1
January 1, 2022
68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Sebastian Bauer, Uta Dirksen, Fadi Zarrad, Michael Nader, Michal Chodyla, Aleksandar Milosevic, Lale Umutlu, Martin Schuler, Lars Erik Podleska, Hans-Ulrich Schildhaus, Wolfgang P. Fendler, Rainer Hamacher
Journal of Nuclear Medicine Jan 2022, 63 (1) 89-95; DOI: 10.2967/jnumed.121.262096
68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Sebastian Bauer, Uta Dirksen, Fadi Zarrad, Michael Nader, Michal Chodyla, Aleksandar Milosevic, Lale Umutlu, Martin Schuler, Lars Erik Podleska, Hans-Ulrich Schildhaus, Wolfgang P. Fendler, Rainer Hamacher
Journal of Nuclear Medicine Jan 2022, 63 (1) 89-95; DOI: 10.2967/jnumed.121.262096
Jump to section
Related Articles
Cited By...
- Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
- 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- 18F-FDG PET/CT in the Management of Osteosarcoma
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- 18F-FDG PET/CT in the Management of Osteosarcoma
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
- Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis